Goldman Sachs
PEARW

Goldman Sachs’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Goldman Sachs’s Portfolio PEARW Stock Details PEARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,180
Closed -$13K – 6651
2021
Q1 		$13K Buy
+13,180
New +$12.9K ﹤0.01% 6025

Other funds holding PEARW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Goldman Sachs's PEARW Position: Q2 2021 in Review

Goldman Sachs sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2021, closing a stake of 13,180 shares — an estimated $13K sold.

Goldman Sachs first reported a position in PEARW in Q1 2021 and held it in 1 quarter. The position peaked at $13K in Q1 2021. 45 funds tracked by Wall St. Rank hold PEARW as of Q2 2021.

  • Goldman Sachs reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2021 after selling out during the quarter.
  • Goldman Sachs sold 13,180 Pear Therapeutics, Inc. Warrant shares in Q2 2021, an estimated $13K.
  • Goldman Sachs first reported a position in Pear Therapeutics, Inc. Warrant in Q1 2021 and held it in 1 quarter.
  • Goldman Sachs's Pear Therapeutics, Inc. Warrant position peaked at $13K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2021.

Based on Goldman Sachs's 13F filing for Q2 2021, filed 13 Aug 2021.